US HB6033 | 2015-2016 | 114th Congress
Status
Spectrum: Slight Partisan Bill (Democrat 2-1)
Status: Introduced on September 14 2016 - 25% progression, died in committee
Action: 2016-09-14 - Referred to the House Committee on Energy and Commerce.
Pending: House Energy And Commerce Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on September 14 2016 - 25% progression, died in committee
Action: 2016-09-14 - Referred to the House Committee on Energy and Commerce.
Pending: House Energy And Commerce Committee
Text: Latest bill text (Introduced) [PDF]
Summary
Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act This bill amends the Federal Food, Drug, and Cosmetic Act to add Middle East respiratory syndrome to the list of tropical diseases under the priority review voucher program, which awards a voucher to the sponsor of a new drug or biological product that is approved to prevent or treat a tropical disease. (A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.)
Title
Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act
Sponsors
Rep. Scott Peters [D-CA] | Rep. Keith Rothfus [R-PA] | Rep. Brendan Boyle [D-PA] |
History
Date | Chamber | Action |
---|---|---|
2016-09-14 | House | Referred to the House Committee on Energy and Commerce. |
2016-09-14 | House | Introduced in House |
Subjects
US Congress State Sources
Type | Source |
---|---|
Summary | https://www.congress.gov/bill/114th-congress/house-bill/6033/all-info |
Text | https://www.congress.gov/114/bills/hr6033/BILLS-114hr6033ih.pdf |